Dianthus Therapeutics to Participate in Two Investor Conferences
Rhea-AI Summary
Dianthus Therapeutics (Nasdaq: DNTH) will participate in two investor conferences in June 2026. Executives will join fireside chats and host one-on-one investor meetings at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference.
Live webcasts will be available via the company’s investor relations website under “News and Events”.
Positive
- None.
Negative
- None.
News Market Reaction – DNTH
In the May 27 session, DNTH declined 0.17%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | Earnings and pipeline | Positive | +0.2% | Q1 2026 results, trial progress, Orphan Drug Designation, and strong cash runway. |
| May 01 | Inducement grants | Neutral | +2.2% | Stock option inducement awards to new employees under Nasdaq Rule 5635(c)(4). |
| Apr 06 | Inducement grants | Neutral | +0.8% | Additional non-qualified stock option grants to new non-executive employees. |
| Mar 12 | Offering closing | Negative | -3.1% | Closing of upsized public offering raising about $719M in gross proceeds. |
| Mar 10 | Offering pricing | Negative | -1.2% | Pricing of upsized $625M underwritten public offering with common shares and warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent financing and earnings news generally saw price moves that aligned with the apparent tone: modest gains on operational updates and declines on dilutive offerings.
Over the last few months, Dianthus reported Q1 2026 results with an early GO decision in its CAPTIVATE CIDP trial, Orphan Drug Designation for claseprubart, and a planned Phase 3 gMG trial, alongside an upsized public offering raising about $719M. Additional news included multiple inducement option grants in April and May 2026. The current conference participation notice follows a period of capital raising and expanding clinical activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in two investor conferences in June 2026.
Ryan Savitz, EVP, CFO and CBO of Dianthus Therapeutics, will participate in a fireside chat on Wednesday, June 3, 2026, at 12:45 p.m. ET and will host one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference.
Marino Garcia, CEO of Dianthus Therapeutics, will participate in a fireside chat on Tuesday, June 9, 2026, at 2:40 p.m. ET and will host one-on-one investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference.
Webcasts of these presentations may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
